Summary
This record appears to document the regulatory approval timeline for GLP-1 receptor agonist medications for weight management in the United Kingdom. The source material suggests that Saxenda was approved for private use in 2017, followed by NHS approval in 2020, with Wegovy approved in 2023 and Mounjaro in 2024. Without access to the full document, this represents a policy or regulatory factsheet rather than peer-reviewed research on farming systems or soil health.
UK applicability
This record is directly applicable to UK policy and practice, documenting the regulatory pathway and timing of GLP-1 receptor agonist approvals. However, this document sits outside the Vitagri Pulse Brain's core remit of peer-reviewed research on farming systems, soil health, and nutrient density.
Key measures
Regulatory approval dates and status for GLP-1 receptor agonist medications (Saxenda, Wegovy, Mounjaro) in NHS and private settings
Outcomes reported
As suggested by the title and context, this record documents the approval status and timeline of Wegovy (semaglutide) and related GLP-1 receptor agonists for weight management in the United Kingdom as of 2023.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.